The following is a summary of “Impact of frailty on outcomes following coronary artery bypass grafting: a systematic review ...

XyloCor Therapeutics, Inc., ("XyloCor"), a clinical stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced the completion of a $67.5 million Series ...

ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ...

XyloCor Therapeutics Inc., a Wayne gene therapy company, received $67.5 million from investors to support Phase 2 trials of a treatment designed to grow new blood vessels in the heart, XyloCor ...

As 2024 came to a close, Ascension Saint Thomas leadership reflected on strides in healthcare innovation, community care and ...

Figure. Landmark events in the evolution of coronary artery bypass grafting (CABG). CAD indicates coronary artery disease; CPB, cardiopulmonary bypass; IPDMA, individual patient data meta-analysis; ...

Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve ...

A new type of bioengineered blood vessel has shown strong results in treating severe vascular injuries, potentially offering ...

donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for ...

With the highest quality materials, a unique manufacturing technique and advanced sealant technology, the AlboGraft Vascular Graft offers an ideal combination of superior softness and sealing.

HEMASHIELD PLATINUM Woven Double Velour Grafts are collagen-impregnated and come in straight, one-branch, or multi-branch graft configurations for aortic repair. Trusted for more than 20 years ...

Therefore, a prospective randomized trial is needed now to validate the safety and efficacy of the SVR procedure, in addition to CABG and optimal medical therapy for HF and CAD, before it is accepted ...